LITE · Q3 2026 Earnings
BullishLumentum
Reported May 5, 2026
30-second summary
Lumentum beat its Q3 FY26 guide on every line — revenue $808.4M (+90% YoY, +22% QoQ) above the midpoint, non-GAAP EPS $2.37 vs. a $2.15–$2.35 guide, non-GAAP operating margin 32.2% vs. a 30.0–31.0% guide — and guided Q4 FY26 to $960M–$1.01B revenue (+100% to +110% YoY off the $480M Q4 FY25 base) and 35.0–36.0% non-GAAP operating margin. The story this quarter is that pump lasers have joined EMLs and OCS as a >30% supply-short product, and management is now openly making customer allocation choices across the company — supply is the binding constraint on every growth vector.
Headline numbers
EPS
Q3 FY2026
$2.37
Revenue
Q3 FY2026
$0.81B
+90.1% YoY
Gross margin
Q3 FY2026
44.2%
Operating margin
Q3 FY2026
21.6%
Key financials
Q3 FY2026| Metric | Q3 FY2026 | YoY | Q2 FY2026 | QoQ |
|---|---|---|---|---|
| Revenue | $0.81B | +90.1% | $0.67B | +21.5% |
| EPS | $2.37 | — | $1.67 | +41.9% |
| Gross margin | 44.2% | — | 36.1% | +810bps |
| Operating margin | 21.6% | — | 9.7% | +1190bps |
Guidance
Lumentum beat Q3 FY2026 guidance across revenue, EPS, and operating margin, with significant upside to profitability metrics; Q4 FY2026 guidance projects another record quarter with ~100%+ YoY growth and substantial margin expansion to 35–36% non-GAAP operating margin.
Guidance is issued for both next quarter and the full year. Both may appear below.
Actuals vs prior guidance
| Metric | Period | Prior guide | Actual | Δ | Result |
|---|---|---|---|---|---|
| Revenue | Q3 FY2026 | $0.78B to $0.83B | $0.8084B | +$0.0084B above midpoint (top 3% of range) | Beat |
| Non-GAAP EPS | Q3 FY2026 | $2.15 to $2.35 | $2.37 | +$0.02 above high end | Beat |
| Non-GAAP Operating Margin | Q3 FY2026 | 30.0% to 31.0% | 32.2% | +110 bps above high end | Beat |
New guidance
| Metric | Period | Guide | YoY |
|---|---|---|---|
| Revenue | Q4 FY2026 | $0.96B to $1.01B | +100-110% YoY |
| Non-GAAP EPS | Q4 FY2026 | $2.85 to $3.05 | — |
| Non-GAAP Operating Margin | Q4 FY2026 | 35.0% to 36.0% | — |
Product revenue
Q3 FY2026| Segment | Q3 FY2026 | YoY |
|---|---|---|
| Components | $0.533B | +77.3% |
| Systems | $0.275B | +121.1% |
| Components Revenue Mix | 66.0% | — |
| Systems Revenue Mix | 34.0% | — |
Management tone
Narrative arc: Q4 FY25 "AI inflection, $600M target" → Q1 FY26 "supply gap widening to 25–30%" → Q2 FY26 "pricing flowing into 40s, $400M+ OCS backlog" → Q3 FY26 "supply allocation choices across the company, $2B goal explicitly on track."
Supply constraints have progressed from a single product to a portfolio-wide allocation problem across four consecutive quarters. In Q4 FY25 the bottleneck was EML wafer capacity. In Q1 FY26 the gap widened to 25–30% on EMLs. In Q2 FY26 management disclosed the gap was holding at ~30% on EMLs while capacity was added. This quarter Mizuho's exchange pulled out that pump lasers — a product line not previously flagged as constrained — now carry a >30% imbalance described as "unanticipated" and arriving "relatively suddenly," with a four-quarter ramp plan at the Rose Orchard facility. Management's verbatim line: "supply constraints on critical components keep our shipments well below customer demand…we're having to make choices across the company in order to service them." Allocation across the company is a different posture than allocation within a single product — it signals demand has outrun planning in ways internal capacity models did not anticipate.
The narrative center has shifted from revenue growth justification to margin expansion mechanics. Management's exact framing from this call: "While we have spent the last few calls detailing our revenue growth drivers, it is important to outline the considerable role the Scale Across portfolio will play in our ability to expand gross and operating margins." Three quarters ago the question was whether the AI demand was durable; two quarters ago whether pricing would flow through; last quarter management confirmed pricing was landing in the 40s. This quarter the framing pivots forward — margin expansion is now the value-creation narrative, and the Q4 guide of 35–36% operating margin (vs. 32.2% just printed) is the immediate proof point. For a company that printed 15.0% non-GAAP operating margin in Q4 FY25, the trajectory is 2,140bps YoY this quarter.
The $2B quarterly revenue goal moved from aspirational OFC framing to "very much on track." Last quarter's $400M+ OCS backlog and Q3 $805M guide had analysts modeling the $2B target as a calendar 2027 outcome. This quarter management restated the goal with high-conviction language ("very much on track") and the Q4 $985M guide places the company at 49% of the milestone. Combined with the disclosure that additional OCS wins are "quite sizable" and "on order of 2027 backlog expectations," the path is materially de-risked from prior quarters where each forward marker (first $600M, then $750M, then $805M) was being pulled in two quarters at a time.
CPO and OCS moved from "validated revenue streams" to "primary sequential growth drivers." In Q1 FY26, OCS and CPO were "next major growth engines not yet contributing meaningfully." In Q2 FY26, OCS backlog was disclosed at $400M+. This quarter Susquehanna's Q&A confirmed $400M of OCS revenue in the back half of FY26 alone, with management calling OCS "the biggest single tight rope" in the supply chain — senior leadership has been personally assigned to manage it. Management's framing of "over half of sequential growth will stem from our components business" with "additional contributions from OCS" places both at the center of the Q4 acceleration, not at the edges.
Pump lasers are the new hidden bottleneck — and the most important new disclosure this quarter. Mizuho's exchange surfaced a constraint that no prior quarter touched: pump laser and narrow-line-width laser supply is now more constrained than EMLs, with multi-rail Scale-Across content increasing pump requirements per system. A four-quarter capacity ramp is underway at Rose Orchard with "significant CapEx." This is the same arc EML capacity followed 18 months ago — disclosure, ramp, then pricing leverage — and management's Citi response that customer LTA extensions and pricing flexibility are persisting suggests pump lasers will likely become the next pricing lever once supply catches demand.
Recurring themes management leaned on this quarter:
Risks management surfaced:
Q&A highlights
Ryan Kuntz · Needham & Co.
Discussed EML and laser supply dynamics, production ramp capabilities, supply-demand gap, and the multi-rail opportunity in scale-across components including pump lasers and narrow line width lasers.
Management confirmed 50% YoY supply increase (Dec to Dec) but still lagging demand by >30%. Supply constraints are mostly internal execution issues near-term; 2027 will require massive laser output scaling. Pump lasers and narrow line width lasers are more constrained than EMLs, particularly for coherent sub-assemblies. Multi-rail opportunities are significant margin drivers but full quantification not yet available.
Samik Chatterjee · JP Morgan
Two questions: (1) OCS customer engagement status and timing of additional award wins relative to OFC announcement; (2) Revenue guidance acceleration drivers between March and June quarters given supply constraints, and which areas will accelerate.
Working with three OCS customers; two represent majority of volume. Additional wins are 'quite sizable' and on order of 2027 backlog expectations, but timing unclear. June quarter acceleration driven primarily by transceivers (1.6T ahead of schedule), with scale-across components and EMLs also stepping up. OCS incrementing. Transceiver supply constraint is primary limiting factor due to electrical components and laser diodes, necessitating shift to internal laser diodes. Margin improvement expected despite growing transceiver business.
Vijay Rakesh · Mizuho
Asked about pump laser demand mix on scale-across and whether supply-demand imbalance of 30% will persist into next year; also queried impact of Google V8 inference and trading rack announcements on OCS pull.
Pump laser constraints are 'unanticipated' and arrived 'relatively suddenly'; imbalance greater than 30% with significant undershipment requiring allocation choices. Ramp plan in place over next 4 quarters from Rose Orchard facility with substantial CapEx. Google V8 vs. V7 OCS pull difference is 'incremental, not that big' but expansion would drive significant upside if secured.
Papa Sila · Citi
Long-term question on CPO scale opportunity with focus on ultra-high power lasers and vertical integration strategy; also asked on oversupply risk given competitors providing large growth numbers.
ELS vertical integration opportunity is 'very significant' and 'around the corner' for conversion to revenue numbers. Non-primary customer engagements primarily driven by ELS initially. CPO expansion will require vertical integration strategy. On oversupply risk: described as 'low' based on customer conversations around extending LTAs and lack of reticence in discussions. Pricing flexibility and ongoing LTA extensions indicate supply-demand imbalance will persist. Competitors adding supply but ground reality differs from projections.
Christopher Rowland · Susquehanna
Asked for deeper clarity on OCS supply constraints; inquired about competitive threat from Chinese OCS competitors showcased at OFC and viability of competing against Lumentum's MEMS technology.
OCS is the 'biggest single tight rope' the company is walking, alongside pump lasers and high-powered lasers. Assigned supply chain responsibility to Wajid Ali (senior leadership). Can ship ~$400M in back half; 2027 numbers continuing to step up with belief that supply is under control. Regarding competition: feels 'very, very strong' position with confidence no one can ship innovative solutions in next year. Not standing still on cost reduction and new OCS architectures despite complexity from new customer demands. MEMS believed to be right long-term technology with cost and simplification opportunities.
Answers to last quarter's watch list
What to watch into next quarter
Whether Q4 prints non-GAAP operating margin above the 36.0% guide high end. Three consecutive beats of 120–320bps suggests pricing and mix continue to run ahead of management assumptions. A fourth beat of magnitude would re-anchor the FY27 margin baseline well above current sell-side models.
First disclosure of an FY27 dollar revenue range or a hard $2B quarterly run-rate timeline. Management has explicitly stated they are "very much on track" to the $2B goal but has not committed a fiscal-year arrival date. With Q4 at $985M midpoint, the next escalation in confidence would be a formal forward marker.
Pump laser supply ramp progress at Rose Orchard. Management said the >30% pump laser imbalance has a four-quarter recovery path. Watch whether the gap narrows (signaling capacity is landing) or widens (signaling demand is again outpacing capacity additions).
Whether pricing is taken on pump lasers and narrow-line-width lasers. EMLs went from "untapped pricing lever" to embedded margin tailwind across three quarters. Pump lasers now sit in the same position. Any commentary on LTA pricing structure for pumps would signal the next leg of margin expansion is underway.
OCS customer-count expansion beyond three. Management called additional wins "quite sizable" and comparable to 2027 backlog scale. Disclosure of a fourth or fifth named customer — or a discrete backlog quantification beyond the prior $400M+ figure — would size the FY27 ramp.
CW laser internalization beyond the disclosed ~20%. The first quantified disclosure landed this quarter. Watch whether the percentage steps up in Q4 actuals and whether management quantifies the gross margin contribution discretely.
Sources
- Lumentum Q3 FY2026 Press Release / 8-K Exhibit 99.1, SEC EDGAR — https://www.sec.gov/Archives/edgar/data/1633978/000162828026030530/lite_ex991xq3fy26.htm
- Q&A commentary as captured in extraction inputs (earnings call references)
Get the next brief, free.
We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.
This is not investment advice.